Biology:Velmanase alfa
| Clinical data | |
|---|---|
| Trade names | Lamzede |
| Other names | Velmanase alfa-tycv |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a623015 |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Velmanase alfa, sold under the brand name Lamzede, is a medication used for the treatment of alpha-mannosidosis.[2][3][4] Velmanase alfa is a recombinant human lysosomal alpha-mannosidase.[2][5]
The most common adverse reactions include hypersensitivity reactions including anaphylaxis, a severe, potentially life-threatening allergic reaction.[2]
Velmanase alfa was approved for medical use in the European Union in March 2018,[3][5] and in the United States in February 2023.[2][6] Velmanase alfa is the first enzyme replacement therapy approved in the US for the treatment of the non-central nervous system manifestations of alpha-mannosidosis.[2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
Medical uses
Velmanase alfa is indicated for the treatment of the non-central nervous system manifestations of alpha-mannosidosis.[2]
Alpha-mannosidosis is a rare genetic lysosomal storage disorder.[2] The symptoms of the disorder vary, but often include mild to moderate intellectual disability, hearing loss, weakened immune system, distinctive facial features (e.g., a large head, prominent forehead, and protruding jaw), skeletal abnormalities, and muscle weakness.[2] Alpha-mannosidosis is caused by genetic changes in the MAN2B1 gene, which codes for the lysosomal alpha-mannosidase enzyme.[2] Mutations of the MAN2B1 gene result in the lack of production of the alpha-D-mannosidase enzyme or the production of a defective, inactive form of the enzyme.[2] Alpha-mannosidosis affects about 1 in every 500,000 people worldwide.[2]
History
The effectiveness of velmanase alfa was evaluated in participants with alpha-mannosidosis in a phase III multicenter, randomized, double-blind, placebo-controlled, parallel group study.[2] The trial evaluated the efficacy of velmanase alfa over 52 weeks at a dose of 1 mg/kg given weekly as an intravenous infusion.[2] A total of 25 participants were enrolled (14 males, 11 females), including 13 adult participants (age range: ≥18 to 35 years; mean: 25 years) and 12 pediatric participants (age range: ≥6 to <18 years; mean: 11 years); all participants were White.[2] Fifteen participants (8 adult and 7 pediatric) received velmanase alfa and 10 participants (5 adult and 5 pediatric) received placebo.[2]
Society and culture
Names
Velmanase alfa is the international nonproprietary name.[8]
References
- ↑ "Lamzede- velmanase alfa-tycv injection, powder, lyophilized, for solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36d50a08-60bd-40eb-807c-778d69bf2d2esave.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 "FDA approves first enzyme replacement therapy for rare alpha-mannosidosis". 17 February 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-enzyme-replacement-therapy-rare-alpha-mannosidosis.
This article incorporates text from this source, which is in the public domain.
- ↑ 3.0 3.1 3.2 "Lamzede EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/lamzede.
- ↑ "Alpha-Mannosidosis". GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. July 2019. https://www.ncbi.nlm.nih.gov/books/NBK1396/. Retrieved 29 May 2022.
- ↑ 5.0 5.1 "Chiesi Group receives the European Marketing Authorisation for Lamzede" (Press release). 4 April 2018. Archived from the original on 19 April 2021. Retrieved 24 August 2020.
- ↑ "Chiesi Global Rare Diseases Announces FDA Approval of Lamzede (velmanase alfa-tycv) for Alpha-Mannosidosis" (Press release). Chiesi Global Rare Diseases. 16 February 2023. Archived from the original on 17 February 2023. Retrieved 17 February 2023 – via PR Newswire.
- ↑ (PDF) New Drug Therapy Approvals 2023 (Report). January 2024. https://www.fda.gov/media/175253/download. Retrieved 9 January 2024.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information 30 (1). 2016.
External links
- Clinical trial number NCT01681953 for "A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis" at ClinicalTrials.gov
- Clinical trial number NCT02998879 for "Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis (rhLaman-08)" at ClinicalTrials.gov
- alpha-Mannosidase at the US National Library of Medicine Medical Subject Headings (MeSH)
 |  |
